Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.58 |
| ▸ | ABCB1 | P08183 | 8/20 | 0.57 |
| ▸ | ABCC1 | P33527 | 7/20 | 0.57 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20494987 | 0.85 | HCAR3 (0.53) | HCAR3ABCB1ABCC1KCNMA1CDC25B | |
| SCHEMBL6642291 | 0.83 | ABCB1 (0.57) | HCAR3ABCB1ABCC1KCNMA1CRHBP | |
| SCHEMBL12730350 | 0.83 | HCAR3 (0.61) | HCAR3ABCB1ABCC1KCNMA1CRHBP | |
| SCHEMBL5159865 | 0.82 | L3MBTL1 (0.68) | HCAR3ABCB1ABCC1KCNMA1CRHBP | |
| SCHEMBL2645986 | 0.81 | ABCB1 (0.66) | HCAR3ABCB1ABCC1KCNMA1CRHBP | |
| SCHEMBL17457463 | 0.81 | ABCB1 (0.69) | HCAR3ABCB1ABCC1KCNMA1CRHBP | |
| SCHEMBL17457465 | 0.81 | ABCB1 (0.69) | HCAR3ABCB1ABCC1KCNMA1CRHBP | |
| SCHEMBL11577045 | 0.80 | KCNMA1 (0.56) | ABCB1ABCC1KCNMA1CRHBPCRHR2 | |
| SCHEMBL22439814 | 0.79 | ABCB1 (0.68) | ABCB1ABCC1KCNMA1HTT | |
| SCHEMBL6080692 | 0.79 | ABCB1 (0.59) | HCAR3ABCB1ABCC1KCNMA1CRHBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2024-04-02 | — | — | US | disclosed |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-09 | — | — | US | disclosed |
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-07 | — | — | US | disclosed |
| EP-3433246-B1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2022-05-04 | — | — | EP | disclosed |
| CN-108884068-B | 1-cyano-pyrrolidine derivatives as DUB inhibitors | 特殊治疗有限公司 | 2021-02-26 | — | — | CN | disclosed |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-10-22 | — | — | US | disclosed |
| EP-3433246-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | Mission Therapeutics Limited (GB) | 2019-01-30 | — | — | EP | disclosed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017163078-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DBU INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2017-09-28 | — | — | WO | disclosed |
| US-6200976-B1 | FOR TREATING THROMBOSIS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-13 | — | — | US | disclosed |
| US-6114532-A | ANTICOAGULANT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352339-B2 | 1-cyano-pyrrolidine derivatives as DUB inhibitors | USP30, USP28, USP1 | HCAR3 1688/4885ABCB1 1368/4885ABCC1 2078/4885 |
| US-20220177451-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | HCAR3 1688/4885ABCB1 1368/4885ABCC1 2078/4885 |
| US-11945797-B2 | 1-cyano-pyrrolidine derivatives as dub inhibitors | USP30, USP28, USP1 | HCAR3 1688/4885ABCB1 1368/4885ABCC1 2078/4885 |
| US-20200331888-A1 | 1-CYANO-PYRROLIDINE DERIVATIVES AS DUB INHIBITORS | USP30, USP28, USP1 | HCAR3 1688/4885ABCB1 1368/4885ABCC1 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.